

1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ni et al.

Application Serial No.: 09/042,583

Art Unit: Not yet assigned

Filed: March 17, 1998

Examiner: Not yet assigned

For: **Death Domain Containing Receptor 5**

Attorney Docket No.: **PF366**

#4a 9/25/98
TGray

PRELIMINARY AMENDMENT

Prior to examining the captioned application, applicants respectfully request that the following amendments be entered. Accompanying this Preliminary Amendment is an Information Disclosure Statement.

In the Claims:

22. (Once amended) An isolated nucleic acid molecule comprising a [polynucleotide having a sequence] nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a nucleotide sequence encoding at least 30 contiguous amino acid residues of SEQ ID NO:2 [the nucleotide sequence of clone HAPBU13R (SEQ ID NO:6)];

(b) a nucleotide sequence encoding at least 30 contiguous amino acid residues of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97920 [the nucleotide sequence of clone HSBBU76R (SEQ ID NO:7)];


(c) the nucleotide sequence of a portion of the sequence shown in Figure 1 (SEQ ID NO:1) wherein said portion comprises at least 50 contiguous nucleotides from nucleotide 284 to 1,362; and

(d) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b) or (c) above.

Support for the amendment to claim 22 may be found throughout the specification, for example, see page 26, line 26. Accordingly, no new matter has been introduced.

Respectfully submitted,

Dated: 9/22/98


A. Anders Brookes (Reg. No. 36,373)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 610-5761 (phone)

AAB/mbp

RECEIVED
98 SEP 23 AM 8:06
GROUP 180